Xiaoyu Qu1,2, Megan Othus3,4, Jerry Davison3, Yu Wu1, Liying Yan5, Soheil Meshinchi1, Fabiana Ostronoff1, Elihu H Estey1,2,6, Jerry P Radich1,2, Harry P Erba4,7, Frederick R Appelbaum1,2,4,6, Min Fang1,2,4,8. 1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 2. Seattle Cancer Care Alliance, Seattle, Washington. 3. Public Health Sciences Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 4. SWOG Leukemia Committee, Portland, Oregon. 5. EpigenDx Inc, Boston, Massachusetts. 6. Department of Medicine, University of Washington, Seattle, Washington. 7. Division of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, Alabama. 8. Department of Pathology, University of Washington, Seattle, Washington.
Abstract
BACKGROUND: Aberrant DNA methylation is known to occur in patients with acute myeloid leukemia (AML), whereas methylation signatures and prognostic markers have been proposed. The objective of the current study was to evaluate all CpG sites of the genome and identify prognostic methylation markers for overall survival in patients with AML with normal karyotype (AML-NK). METHODS: AML-NK samples from 7 SWOG trials were analyzed using a novel genome-wide approach called "CHARMcox" (comprehensive high-throughput array-based relative methylation analysis combined with the Cox proportional hazards model) controlling for known clinical covariates. CHARMcox was applied to a phase 1 discovery cohort (72 patients) to identify survival-associated methylation regions (SAMRs). Subsequently, using bisulfite pyrosequencing, SAMRs were studied in phase 2 model-building (65 patients) and phase 3 validation (65 patients) cohorts. An independent external cohort from The Cancer Genome Atlas (TCGA) AML study (LAML) was used for further validation (93 patients). RESULTS: Two SAMRs, located at the CpG island shores of leucine zipper tumor suppressor 2 (LZTS2) and nuclear receptor subfamily 6 group a member 1 (NR6A1), respectively, were identified. Multivariable analyses demonstrated that hypomethylation of either LZTS2 or NR6A1 was associated with worse overall survival in the SWOG cohort (P<.001). The prognosis was validated in patients with AML-NK from the TCGA-LAML cohort. Methylation values below the median at both markers predicted worse overall survival (SWOG: hazard ratio, 1.89 [P<.001]; and TCGA-LAML: hazard ratio, 2.08 [P=.006]). The C-statistic was 0.71 for both cohorts, and the impact was independent of the Fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD) status. CONCLUSIONS: The 2 methylation markers, measurable by clinically applicable assays such as bisulfite pyrosequencing, are promising for risk stratification among patients with AML-NK. Cancer 2017;123:2472-81.
BACKGROUND: Aberrant DNA methylation is known to occur in patients with acute myeloid leukemia (AML), whereas methylation signatures and prognostic markers have been proposed. The objective of the current study was to evaluate all CpG sites of the genome and identify prognostic methylation markers for overall survival in patients with AML with normal karyotype (AML-NK). METHODS:AML-NK samples from 7 SWOG trials were analyzed using a novel genome-wide approach called "CHARMcox" (comprehensive high-throughput array-based relative methylation analysis combined with the Cox proportional hazards model) controlling for known clinical covariates. CHARMcox was applied to a phase 1 discovery cohort (72 patients) to identify survival-associated methylation regions (SAMRs). Subsequently, using bisulfite pyrosequencing, SAMRs were studied in phase 2 model-building (65 patients) and phase 3 validation (65 patients) cohorts. An independent external cohort from The Cancer Genome Atlas (TCGA) AML study (LAML) was used for further validation (93 patients). RESULTS: Two SAMRs, located at the CpG island shores of leucine zipper tumor suppressor 2 (LZTS2) and nuclear receptor subfamily 6 group a member 1 (NR6A1), respectively, were identified. Multivariable analyses demonstrated that hypomethylation of either LZTS2 or NR6A1 was associated with worse overall survival in the SWOG cohort (P<.001). The prognosis was validated in patients with AML-NK from the TCGA-LAML cohort. Methylation values below the median at both markers predicted worse overall survival (SWOG: hazard ratio, 1.89 [P<.001]; and TCGA-LAML: hazard ratio, 2.08 [P=.006]). The C-statistic was 0.71 for both cohorts, and the impact was independent of the Fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD) status. CONCLUSIONS: The 2 methylation markers, measurable by clinically applicable assays such as bisulfite pyrosequencing, are promising for risk stratification among patients with AML-NK. Cancer 2017;123:2472-81.
Authors: Leonie I Kroeze; Mariam G Aslanyan; Arno van Rooij; Theresia N Koorenhof-Scheele; Marion Massop; Thomas Carell; Jan B Boezeman; Jean-Pierre Marie; Constantijn J M Halkes; Theo de Witte; Gerwin Huls; Stefan Suciu; Ron A Wevers; Bert A van der Reijden; Joop H Jansen Journal: Blood Date: 2014-07-01 Impact factor: 22.113
Authors: Kasper Daniel Hansen; Winston Timp; Héctor Corrada Bravo; Sarven Sabunciyan; Benjamin Langmead; Oliver G McDonald; Bo Wen; Hao Wu; Yun Liu; Dinh Diep; Eirikur Briem; Kun Zhang; Rafael A Irizarry; Andrew P Feinberg Journal: Nat Genet Date: 2011-06-26 Impact factor: 38.330
Authors: Rafael A Irizarry; Christine Ladd-Acosta; Andrew P Feinberg; Bo Wen; Zhijin Wu; Carolina Montano; Patrick Onyango; Hengmi Cui; Kevin Gabo; Michael Rongione; Maree Webster; Hong Ji; James Potash; Sarven Sabunciyan Journal: Nat Genet Date: 2009-01-18 Impact factor: 38.330
Authors: Era L Pogosova-Agadjanyan; Anna Moseley; Megan Othus; Frederick R Appelbaum; Thomas R Chauncey; I-Ming L Chen; Harry P Erba; John E Godwin; Min Fang; Kenneth J Kopecky; Alan F List; Galina L Pogosov; Jerald P Radich; Cheryl L Willman; Brent L Wood; Soheil Meshinchi; Derek L Stirewalt Journal: Biopreserv Biobank Date: 2017-11-27 Impact factor: 2.256
Authors: Šárka Šestáková; Ela Cerovská; Cyril Šálek; Dávid Kundrát; Ivana Ježíšková; Adam Folta; Jiří Mayer; Zdeněk Ráčil; Petr Cetkovský; Hana Remešová Journal: Clin Epigenetics Date: 2022-02-11 Impact factor: 6.551